Long-term safety study of lunsekimig for COPD
Treatments studied
Part of Lungs & breathing clinical trials.
This study is a long-term follow-up for people with COPD who have already completed an earlier lunsekimig study. It aims to check the safety and effectiveness of the treatment over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the treatment period in the earlier studies (EFC18243 or EFC18244).
- You agree to use effective contraception during the study and for 8 weeks after the last dose (if applicable).
- You have not developed any new medical condition or worsening of an existing condition that would make the study unsafe.
- You have not had a serious or non-serious side effect related to lunsekimig that would make continuing risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This trial tests if inhaled corticosteroids (ICS) work better for COPD patients with different eosinophil levels. You must already be taking two long-acting bronchodilators and have stopped smoking for at least 6 months.
This trial tests the long-term safety and effectiveness of Lunsekimig, an investigational drug, for adults with asthma. It is for people who have already completed a previous Lunsekimig study and are on stable asthma medications.
This study tests the long-term safety and effectiveness of a medication called lunsekimig for people with chronic sinusitis and nasal polyps. It is for those who already completed a previous study on this drug.
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.